Skip Navigation


NDT Advance Access originally published online on March 7, 2006
Nephrology Dialysis Transplantation 2006 21(7):1863-1869; doi:10.1093/ndt/gfl079
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
21/7/1863    most recent
gfl079v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Macedo, E.
Right arrow Articles by Vieira, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Macedo, E.
Right arrow Articles by Vieira, J. M., Jr
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org


Original Articles: Clinical Nephrology

Lack of protection of N-acetylcysteine (NAC) in acute renal failure related to elective aortic aneurysm repair—a randomized controlled trial

Etienne Macedo1, Regina Abdulkader1, Isac Castro1, Augusto C. C. Sobrinho2, Lius Yu1 and Jose M. Vieira, Jr1

1 Renal Division and 2 Vascular Surgery Division, Hospital das Clínicas, University of São Paulo, São Paulo, Brazil

Correspondence and offprint requests to: Dr José M. Vieira, Jr, Av. Dr Arnaldo 455, Sala 3342, CEP 01246-903, São Paulo-SP, Brazil. Email: josemvjr{at}usp.br

Background. N-acetylcysteine (NAC) is an antioxidant drug largely tested in different clinical situations. Recently, NAC has been employed with variable success in the prevention of radiocontrast nephropathy. Since aortic aneurysm surgical repair is a condition that is frequently accompanied by acute renal failure (ARF), we sought to investigate whether NAC has any role in preventing ARF in this scenario.

Methods. A randomized, placebo-controlled, double-blind trial with the following inclusion criteria: elective aortic aneurysm repair in patients with stable renal function. The groups were randomly matched for age, gender, presence of diabetes and pre-existent renal failure. NAC or placebo (control) was administered p.o. for 24 h before operation and maintained i.v. for 48 h after operation. The dose of NAC was 1200 mg b.i.d. the day before surgery and 600 mg b.i.d. after. The primary endpoint was the development of ARF up to the third post-operative day, defined as an increase in SCr ≥ 25% from baseline. Secondary endpoints were: ICU mortality and ICU length of stay.

Results. Forty-two patients (n = 18 for NAC group and n = 24 for control) were studied. The baseline SCr and calculated GFR did not differ between the groups (1.19±0.33 vs 1.37±0.49 mg/dl; and 64.6±26.22 vs 65.7±28.32 ml/min, NAC vs control, respectively, P = 0.17 and P = 0.90). Need for suprarenal aortic cross-clamping and its duration, occurrence of major bleeding, intra-operative hypotension and the post-operative peak of CPK did not differ between NAC and control groups. The overall incidence of ARF in the study was 36% (13/36), but it was not significantly different between groups (7/14, 50% in NAC vs 6/22, 27.3% in control, P = 0.16). The overall mortality was 23% (10/42) and was not different (P = 0.209) in NAC group (33.3%) when compared with control (16.7%), the same occurring with the length of ICU stay (2.93±1.53 vs 2.52±1.36 days, P = 0.40).

Conclusion. This study suggests that the putative beneficial effects of NAC on radiocontrast nephropathy might not be applicable to other situations, such as ARF associated with elective aortic aneurysm repair.

Keywords: N-acetylcysteine; acute renal failure; aortic aneurysm; ischaemia; randomized controlled trial; surgery


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
CJASNHome page
J. Himmelfarb, M. Joannidis, B. Molitoris, M. Schietz, M. D. Okusa, D. Warnock, F. Laghi, S. L. Goldstein, R. Prielipp, C. R. Parikh, et al.
Evaluation and Initial Management of Acute Kidney Injury
Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 962 - 967.
[Abstract] [Full Text] [PDF]


Home page
Hum Exp ToxicolHome page
M. Sadegh Soltan-Sharifi, M. Mojtahedzadeh, A. Najafi, M. Reza Khajavi, M. Reza Rouini, M. Moradi, A. Mohammadirad, and M. Abdollahi
Improvement by N-acetylcysteine of acute respiratory distress syndrome through increasing intracellular glutathione, and extracellular thiol molecules and anti-oxidant power: evidence for underlying toxicological mechanisms
Human and Experimental Toxicology, September 1, 2007; 26(9): 697 - 703.
[Abstract] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.